Sujan Lahiri

Aeterna Zentaris: Mispriced $1 Biotech Stock With Limited Downside Risk And Big Upside Potential

(Editors' Note: This article covers a micro-cap stock. Please be aware of the risks associated with these stocks.)

Today's article features Aeterna Zentaris (NASDAQ:AEZS), one of the most undervalued biotech companies in the market. This is a small $1 biotech stock which has fallen out of favor with almost all investors. A look at the chart explains why. While the broader biotech indices rallied sharply, Aeterna lost 90% of its market capitalization. This marks a widespread volatility in the sector but also enhances, as we like to elaborate in this article, the opportunity to discover deeply undervalued micro-caps. Selling of this magnitude often pushes shares down to an irrationally low level, creating huge buying opportunities. Aeterna has all...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details